JP2021528104A5 - - Google Patents
Info
- Publication number
- JP2021528104A5 JP2021528104A5 JP2021520275A JP2021520275A JP2021528104A5 JP 2021528104 A5 JP2021528104 A5 JP 2021528104A5 JP 2021520275 A JP2021520275 A JP 2021520275A JP 2021520275 A JP2021520275 A JP 2021520275A JP 2021528104 A5 JP2021528104 A5 JP 2021528104A5
- Authority
- JP
- Japan
- Prior art keywords
- heterogeneous
- antibody
- enables
- extension
- life
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024016792A JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862689051P | 2018-06-22 | 2018-06-22 | |
| US62/689,051 | 2018-06-22 | ||
| PCT/US2019/038210 WO2019246379A1 (en) | 2018-06-22 | 2019-06-20 | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016792A Division JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021528104A JP2021528104A (ja) | 2021-10-21 |
| JPWO2019246379A5 JPWO2019246379A5 (https=) | 2022-06-23 |
| JP2021528104A5 true JP2021528104A5 (https=) | 2022-06-23 |
| JP7440102B2 JP7440102B2 (ja) | 2024-02-28 |
Family
ID=68984274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520275A Active JP7440102B2 (ja) | 2018-06-22 | 2019-06-20 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| JP2024016792A Active JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016792A Active JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12319722B2 (https=) |
| EP (1) | EP3810171B1 (https=) |
| JP (2) | JP7440102B2 (https=) |
| KR (2) | KR102848197B1 (https=) |
| CN (2) | CN121086085A (https=) |
| AU (2) | AU2019288471B2 (https=) |
| CA (1) | CA3102821A1 (https=) |
| WO (1) | WO2019246379A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24546B1 (es) * | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP7807076B2 (ja) * | 2019-12-13 | 2026-01-27 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| IL297326A (en) * | 2020-04-22 | 2022-12-01 | Novartis Ag | Pharmaceutical preparations and pharmaceutical products of human interleukin-15 hydrometers (ethyl-15) |
| KR20250140647A (ko) * | 2020-08-03 | 2025-09-25 | 난트셀, 인크. | Il-15 초작용제에 대한 약물-특이적 약동학 검정 |
| WO2022045849A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 지아이셀 | Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도 |
| AU2021345852A1 (en) * | 2020-09-16 | 2023-05-25 | Beone Medicines I Gmbh | Interleukin 15 constructs and methods of use |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
| WO2022232321A1 (en) * | 2021-04-28 | 2022-11-03 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
| CN113321740B (zh) * | 2021-05-08 | 2023-07-18 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| US20250115657A1 (en) * | 2021-05-28 | 2025-04-10 | Akso Biopharmaceutical, Inc. | Bispecific FC Fusion Proteins with sPD-1 and IL-15 |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN116023503B (zh) * | 2021-10-25 | 2024-05-31 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| WO2023083379A1 (zh) * | 2021-11-15 | 2023-05-19 | 中国科学院生物物理研究所 | 一种以白介素15为活性成份的融合蛋白构建体及其应用 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| WO2024031036A2 (en) * | 2022-08-05 | 2024-02-08 | Staidson Biopharma Inc. | Il-15 prodrug and uses thereof |
| US20260083832A1 (en) * | 2022-10-28 | 2026-03-26 | Nant Holdings Ip, Llc | Vaccine Composition For Stimulation Of Broad Spectrum Memory B Cell Expansion |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| US20060236411A1 (en) | 2002-10-14 | 2006-10-19 | Ingeborg Dreher | Antagonists il-15 |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| NZ582330A (en) | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| WO2016018920A1 (en) | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| AU2015366795B2 (en) | 2014-12-19 | 2020-12-17 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex and use thereof |
| CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| EP3350205A1 (en) | 2015-09-16 | 2018-07-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
-
2019
- 2019-06-20 EP EP19822948.6A patent/EP3810171B1/en active Active
- 2019-06-20 WO PCT/US2019/038210 patent/WO2019246379A1/en not_active Ceased
- 2019-06-20 US US17/254,004 patent/US12319722B2/en active Active
- 2019-06-20 JP JP2021520275A patent/JP7440102B2/ja active Active
- 2019-06-20 KR KR1020217002145A patent/KR102848197B1/ko active Active
- 2019-06-20 CN CN202511239681.1A patent/CN121086085A/zh active Pending
- 2019-06-20 KR KR1020257027222A patent/KR20250130696A/ko active Pending
- 2019-06-20 AU AU2019288471A patent/AU2019288471B2/en active Active
- 2019-06-20 CA CA3102821A patent/CA3102821A1/en active Pending
- 2019-06-20 CN CN201980055119.XA patent/CN112584851B/zh active Active
-
2024
- 2024-02-07 JP JP2024016792A patent/JP7741574B2/ja active Active
-
2025
- 2025-02-19 AU AU2025201175A patent/AU2025201175A1/en active Pending
- 2025-05-03 US US19/197,991 patent/US20250388641A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021528104A5 (https=) | ||
| JPWO2019246379A5 (https=) | ||
| EP3765522A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES | |
| JP2022122972A5 (https=) | ||
| JP2022185040A5 (https=) | ||
| JP2020532288A5 (https=) | ||
| JP2023182571A5 (https=) | ||
| JP2024026077A5 (https=) | ||
| JP2023133317A5 (https=) | ||
| JP2018186833A5 (https=) | ||
| EP3752535A4 (en) | METHOD OF PREPARING THE MONOCLONAL ANTIBODY HU14.18K322A | |
| JP2020079331A5 (https=) | ||
| JP2022064180A5 (https=) | ||
| JP2023116477A5 (https=) | ||
| EP3947466A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
| PL3840756T3 (pl) | Ulepszona synteza 1,4-diazaspiro[5.5]undekan-3-onu | |
| IL286306A (en) | Manufacturing methods for producing anti-tnf antibody compositions | |
| JP2023145479A5 (https=) | ||
| JP2023078311A5 (https=) | ||
| JPWO2021132591A5 (https=) | ||
| JP2023012502A5 (https=) | ||
| JP2015119721A5 (https=) | ||
| JPWO2021172498A5 (https=) | ||
| JOP20210100A1 (ar) | جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20 | |
| JPWO2019199363A5 (https=) |